Invivyd, Inc.
For the period ended May 14, 2026. Filed May 14, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
May 14, 2026 · Filed May 14, 2026
Use the contents to explore the available documents and sections.
Contents
EX-99.1 · About DECLARATION
About DECLARATION
DECLARATION (NCT07298434) is a Phase 3, randomized, triple-blind, placebo-controlled trial to evaluate VYD2311 efficacy and safety in prevention of symptomatic COVID in a broad population of participants including adults and adolescents both with and without risk factors for progression to severe COVID-19, at three months. Participants will receive either a single dose or a monthly dose of VYD2311, each administered via intramuscular (IM) injection, compared to placebo. Total enrollment of the trial is expected to be approximately 2,301 participants.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.